The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial

Chris Skedgel, Daniel Rayson, Tallal Younis

Research output: Contribution to journalArticlepeer-review

31 Citations (Scopus)


The efficacy of sequential adjuvant trastuzumab (aTZ) after chemotherapy in women with early-stage human epidermal growth factor-2 (HER2/neu)-positive breast cancer reported by the updated Herceptin Adjuvant (HERA) trial appears less favorable than originally reported. Based on these updated results, we estimated the cost-utility (CU) of sequential aTZ relative to chemotherapy alone in terms of incremental cost per quality-adjusted life-year (QALY) gained.
Original languageEnglish
Pages (from-to)641-648
Number of pages8
JournalValue in Health
Issue number5
Publication statusPublished - Jul 2009


  • breast cancer
  • cost-utility
  • net-benefits
  • relative risk
  • trastuzumab

Cite this